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OBJECTIVE — Because of blood lipid concerns, diabetes associations discourage fructose at
high intakes. To quantify the effect of fructose on blood lipids in diabetes, we conducted a
systematic review and meta-analysis of experimental clinical trials investigating the effect of
isocaloricfructoseexchangeforcarbohydrateontriglycerides,totalcholesterol,LDLcholesterol,
and HDL cholesterol in type 1 and 2 diabetes.
RESEARCH DESIGN AND METHODS — We searched MEDLINE, EMBASE,
CINAHL, and the Cochrane Library for relevant trials of 7 days. Data were pooled by the
generic inverse variance method and expressed as standardized mean differences with 95% CI.
Heterogeneity was assessed by 
2 tests and quantiﬁed by I
2. Meta-regression models identiﬁed
dose threshold and independent predictors of effects.
RESULTS — Sixteen trials (236 subjects) met the eligibility criteria. Isocaloric fructose ex-
change for carbohydrate raised triglycerides and lowered total cholesterol under speciﬁc condi-
tions without affecting LDL cholesterol or HDL cholesterol. A triglyceride-raising effect without
heterogeneity was seen only in type 2 diabetes when the reference carbohydrate was starch
(mean difference 0.24 [95% CI 0.05–0.44]), dose was 60 g/day (0.18 [0.00–0.37]), or fol-
low-up was 4 weeks (0.18 [0.00–0.35]). Piecewise meta-regression conﬁrmed a dose thresh-
oldof60g/day(R
20.13)/10%energy(R
20.36).Atotalcholesterol–loweringeffectwithout
heterogeneitywasseenonlyintype2diabetesunderthefollowingconditions:norandomization
and poor study quality (0.19 [0.34 to 0.05]), dietary fat 30% energy (0.33 [0.52 to
0.15]), or crystalline fructose (0.28 [0.47 to 0.09]). Multivariate meta-regression anal-
yses were largely in agreement.
CONCLUSIONS — Pooled analyses demonstrated conditional triglyceride-raising and total
cholesterol–lowering effects of isocaloric fructose exchange for carbohydrate in type 2 diabetes.
Recommendations and large-scale future trials need to address the heterogeneity in the data.
Diabetes Care 32:1930–1937, 2009
A
lthough the National Cholesterol
Education Program in the Adult
Treatment Panel III guidelines (1)
identiﬁed LDL cholesterol as the most
atherogenic lipid fraction and primary
target of cholesterol-lowering therapy for
coronary heart disease, raised triglycer-
ides (TGs) have been consistently associ-
ated with increased coronary heart
disease risk even after adjustment for es-
tablished coronary risk factors (2). The
association is especially heightened in the
context of a non–LDL cholesterol athero-
genic dyslipidemia consisting of raised
TGs and low HDL cholesterol, a pattern
commonlymanifestintype2diabetes(3).
Among sugars, fructose has been sin-
gled out in guidelines for its effect on
bloodlipids.Specialconcernhasbeenex-
pressedaboutusingfructoseasanutritive
sweetener in conditions that predispose
to higher TG levels, such as diabetes. The
American Diabetes Association (15–
20% energy) (4), Canadian Diabetes As-
sociation (CDA) (60 g/day, 12%
energy)(5),andEuropeanAssociationfor
the Study of Diabetes (17% energy) (6)
discourage fructose at high intakes, citing
its ability to affect lipids adversely. The
data on which these recommendations
are based, however, are inconsistent with
new evidence that the dose threshold for
TG effects may lie at 100 g/day (7),
whichexceedseventhe95thpercentileof
U.S. fructose intake (8). There is also par-
adoxical evidence that fructose may im-
prove long-term glycemic control (7). To
clarify the effect of fructose on lipid con-
trol in individuals with diabetes, we con-
ducted a systematic review and meta-
analysis of controlled, experimental trials
assessingtheeffectofisocaloric,oralfruc-
tose exchange for carbohydrate on TGs,
total cholesterol, LDL cholesterol, and
HDL cholesterol in individuals with
diabetes.
RESEARCH DESIGN AND
METHODS— We followed the Co-
chrane Handbook for Systematic Reviews of
Interventionsfortheplanningandconduct
of this meta-analysis (9). The reporting
followed Quality of Reporting of Meta-
Analyses guidelines (10).
Study selection
We conducted a search of MEDLINE
(1950–20 February 2009), EMBASE
(1980–5 February 2008), CINAHL
(1982–5 February 2008), and the Co-
chrane Library, including the Cochrane
Central Register of Controlled Trials
(Clinical Trials; CENTRAL) database
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1930 DIABETES CARE, VOLUME 32, NUMBER 10, OCTOBER 2009 care.diabetesjournals.org(1800-20 February 2009), using the fol-
lowing search terms and Boolean opera-
tors: fructose AND (triglyceride OR
triacylglycerol OR VLDL OR VLDL OR li-
pemia OR lipaemia OR lipids OR choles-
terol).Thesearchwasrestrictedtohuman
research studies. No limit was placed on
language.Manualsearchessupplemented
thedatabasesearchstrategy.Weincluded
clinical intervention trials that investi-
gated the chronic effect of exchanging
oral fructose for carbohydrate on lipids in
individuals with type 2 diabetes. Studies
thathad7daysfollow-up,administered
fructose intravenously, lacked an ade-
quate carbohydrate control, reported ei-
ther hypercaloric, nonisoglucidic, or
unbalanced comparisons, and/or re-
ported only nonfasting results were ex-
cluded. If multiple publications existed
for the same study, the article with the
most information was included.
Data extraction
Two investigators (J.L.S., A.J.C.) inde-
pendently extracted relevant data on
study characteristics and outcomes using
a standardized proforma. These data in-
cluded information about study design
(parallel,crossover,factorial,andothers),
randomization, blinding, sample size and
subject characteristics (age, sex, BMI, and
diabetes status), fructose format, dose,
reference carbohydrates used as controls
(starch, sucrose, or mixed carbohydrates
[undeﬁned combination]), follow-up,
and macronutrient proﬁle of the back-
grounddiet.MeansSEMposttreatment
valuesforTGs,totalcholesterol,LDLcho-
lesterol, and HDL cholesterol were ex-
tracted as the main end points. Studies
that did not report mean and/or SEM val-
ues had these values imputed from SD,
95% CI, P values, or t, F, or Tukey hon-
estlysigniﬁcantdifferencestatistics,using
standard formulas (11). If these data were
unavailable, then SEM was extrapolated
by imputing the pooled SEM from the
other studies included in the meta-
analysis (12,13). For studies that differed
in units, units were converted using stan-
dardconversionfactors.Theinvestigators
also assessed the quality of each study us-
ing the Heyland score (14), which assigns
a score from 0–1 or 0–2 over nine cate-
gories of quality related to study design,
sampling procedures, and interventions
for a total of 13 points. Studies that re-
ported 100% follow-up data were scored
as intent-to-treat analyses. Metabolically
controlleddesignswerealsorecordedasa
measure of study quality. Disagreements
were reconciled by consensus after dis-
cussion with other investigators (R.J.D.,
D.J.A.J.). Authors were not contacted to
request additional information.
Statistical analyses
Data were analyzed using Review Man-
ager (RevMan 5.0.16; Cochrane Library
software, Oxford, U.K.). Separate pooled
analyseswereconductedforanydiabetes,
type 1 diabetes, and type 2 diabetes using
the generic inverse variance ﬁxed
method. Outcomes included end differ-
ences for TG, total cholesterol, LDL cho-
lesterol, and HDL cholesterol. Random-
effect models were applied when
heterogeneity was signiﬁcant with ﬁxed-
effects models being used otherwise.
Paired analyses were applied to all cross-
over trials (13), necessitating that data be
expressed as standardized mean differ-
ences (SMDs) with 95% CI, where 0.4
represents a small effect size, 0.4–0.7
represents a moderate effect size, and
0.7 represents a large effect size. To ad-
dressaunit-of-analysiserrorfrominclud-
ingtrialswithmultipleinterventionarms,
we combined arms to create single pair-
wise comparisons. Interstudy heteroge-
neity was tested by Cochrane’s Q (
2)
(P  0.10) and quantiﬁed by I
2, where I
2
 50% is evidence of substantial hetero-
geneity and I
2  75% is evidence of con-
siderable heterogeneity (11). Sources of
heterogeneity were investigated by sensi-
tivityanalysesandapriorisubgroupanal-
yses, investigating the effect of reference
carbohydrates (starch, sucrose, and
mixed carbohydrates), fructose format
(crystalline, ﬂuid, and mixed format),
dose (CDA thresholds 60 g/day or 60
g/day[5]),lengthoffollow-up(4weeks
or 4 weeks), study quality (Heyland
Methodological Quality Score [MQS] 8
and 8 [14]), and randomization. Addi-
tional post hoc subgroup analyses were
undertaken to investigate the effect of
feeding control (metabolic or nonmeta-
bolic), design (paralleled or crossover),
washout in crossover studies (yes or no),
and background diet. Inverse variance
weighted piecewise polynomial regres-
sion models were used to estimate dose
thresholds. To assess independent pre-
dictors of the isocaloric exchange of fruc-
tose for carbohydrate, we used multiple
regression models with inverse variance
weighting selected by all possible regres-
sion using the R
2 criterion (NCSS [Num-
berCruncherStatisticalSystem]software,
Kaysville, Utah). Publication bias was in-
vestigated by inspection of funnel plots.
RESULTS
Search results
Figure 1 shows the ﬂow of the literature
applying the systematic search and selec-
tion strategies to identify eligible reports;
786 reports were identiﬁed by the search.
Of these, 690 were determined to be ir-
relevant on review of the titles and ab-
stracts. The remaining 96 reports were
retrieved and reviewed in full, of which
82 were excluded. A total of 14 reports
(16 trials) were selected for pooled
analyses.
Trial characteristics
Table1showsthecharacteristicsofthe16
included trials, which contained 20 com-
parisons in 236 subjects with type 1 dia-
betes(4trials,n54),type2diabetes(11
trials,n156),andundifferentiatedtype
1 and type 2 diabetes (1 trial, n  26)
(15–28). Nine trials were randomized.
Eleven trials used crossover designs.
Starch, sucrose, or mixed carbohydrates
were used as the reference carbohydrate
(comparator). Fructose was administered
in crystalline, liquid, or mixed formats at
dosesfrom30to160g/day,withsixtrials
exceedingtheCDAthresholdof60g/day.
Eighttrialsweremetabolicallycontrolled,
providing all foods consumed. Back-
grounddietswere40–55%carbohydrate,
25–38% fat, and 15–20% protein. Fol-
low-up was from 8 days to 52 weeks. The
Heyland MQS ranged from 4 to 8 with
ninetrialsconsideredtobeofhighquality
(MQS 8).
Primary analyses
Table2showstheeffectofisocaloricfruc-
tose exchange for carbohydrate on TG,
total cholesterol, LCL cholesterol, and
HDL cholesterol as assessed in the 14 in-
cluded trials in individuals with any, type
1, or type 2 diabetes. No effect of isoca-
loric exchange of fructose for carbohy-
drate was seen for any outcome. There
was, however, evidence of considerable
interstudy heterogeneity for TG, total
cholesterol, and HDL cholesterol (I
2 
75%, P  0.10). Systematic removal of
each trial during sensitivity analyses,
however,explainedsomeoftheheteroge-
neity. Removal of Pelkonen et al. (16) for
TG in the type 1 diabetes analysis, Osei et
al. (20) for TG, and Osei and Bossetti
(24) for HDL cholesterol in the type 2
diabetes analyses eliminated the evi-
dence for heterogeneity without alter-
ing the conclusions.
Sievenpiper and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 32, NUMBER 10, OCTOBER 2009 1931Type 1 diabetes subgroup analyses
A priori and post hoc subgroup analyses
were used to explore the effect of sources
of heterogeneity in type 1 diabetes (sup-
plementary Table A1, available at http://
care.diabetesjournals.org/cgi/content/full/
dc09-0619/DC1). None of the subgroup
analyses were signiﬁcant for any out-
come, except for total cholesterol, for
which they were driven by the single
study (25) included in the analysis. Data
from only one study were included in the
LDL cholesterol and HDL cholesterol
pooled analyses. Evidence for heteroge-
neity was signiﬁcant only in the one cate-
goryofeachsubgroupanalysiscontaining
Pelkonenetal.(16),theremovalofwhich
reduced heterogeneity to nonsigniﬁcant
levels (I
2  50%, P  0.10) without al-
tering conclusions.
Type 2 diabetes subgroup analyses
A priori and post hoc subgroup analyses
were used to explore the effect of sources
Figure 1—Flow of the literature.
Fructose and blood lipids in diabetes
1932 DIABETES CARE, VOLUME 32, NUMBER 10, OCTOBER 2009 care.diabetesjournals.orgof heterogeneity in type 2 diabetes (sup-
plementary Table A2, available in an on-
line appendix). These analyses showed a
small TG-raising effect of fructose ex-
change for carbohydrate under speciﬁc
conditions: starch as the reference carbo-
hydrate, dose 60 g/day (lower dose
limit), or follow-up 4 weeks (Fig. 2).
Dose thresholds were further explored by
piecewise polynomial meta-regression
(quadratic-quadratic) models, which
conﬁrmedthesamedosebreakpointof60
g/day (R
2  0.13) or 10% energy (R
2 
0.36). Conversely, a TG-lowering effect
was seen only in trials with parallel de-
signs. The interstudy heterogeneity seen
for TGs was largely explained by these
subgroups. It became nonsigniﬁcant in
every subgroup category with the excep-
tion of those categories containing Osei et
al. (20), the removal of which explained
heterogeneity (I
2  0–5%, P  0.10)
without altering conclusions.
A total cholesterol–lowering effect
was seen only in type 2 diabetes under
speciﬁc conditions. These included no
randomizationandpoorstudyquality,no
metabolic feeding control, crystalline
fructose,ordietaryfat30%energy(Fig.
2). Among these signiﬁcant subgroup
analyses,therewasevidenceofinterstudy
heterogeneity in only the analysis for no
metabolicfeedingcontrol.Interstudyhet-
erogeneity remained unexplained for this
subgroup analysis and the other nonsig-
niﬁcant subgroup analyses.
No effect of subgroup analyses was
seen on LDL cholesterol or HDL choles-
terol. Interstudy heterogeneity was only
signiﬁcant for HDL cholesterol in each
category containing the study of Osei and
Bossetti(24),theremovalofwhichduring
sensitivityanalysesexplainedheterogene-
ity (I
2  0%, P  0.10) without altering
conclusions.
Multivariate analyses
To explore further the heterogeneity
identiﬁed in univariate analyses for TG
and total cholesterol, multiple regres-
sion models assessed the independent
predictors of these outcomes in the
complete dataset combining subjects
withtype1andtype2diabetes(supple-
mentaryTableA3,availableinanonline
appendix). The models were signiﬁcant
(P  0.05) for both outcomes, explain-
ing 72–86% of the variability in out-
comes. A crossover design was found to
be the strongest independent predictor
of TG followed by metabolic feeding
control, follow-up, ﬂuid format, dose,
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Follow-upwasfoundtobethestrongest
independent predictor of total choles-
terol followed by dose.
Publication bias
Funnel plots for each of the analyses were
inspected for the presence of publication
bias (supplementary Fig. A1, available in
an online appendix). There was limited
evidence of funnel plot asymmetry for
TG, with two small trials reporting large
effects and error estimates that favored
fructose but no small trials favoring any
carbohydrate. No asymmetry was ob-
served for total cholesterol, LDL choles-
terol, and HDL cholesterol.
CONCLUSIONS — The present
pooled analyses of 16 controlled experi-
mental trials in 236 subjects with type 1
and type 2 diabetes demonstrate heteroge-
neous lipid effects of isocaloric exchange of
fructose for other carbohydrates. Condi-
tional TG-increasing and total cholesterol–
loweringeffectswereseenonlyinsubjects
withtype2diabetes.Nootherlipideffects
were seen. Expressed as mean differences
(mean difference  SMD  pooled SD),
the modest SMD increases in TG of
0.17–0.23 mmol/l and decreases in to-
tal cholesterol of 0.17 to 0.29
mmol/l were dependent on speciﬁc trial
conditions.
FructosewasfoundtoraiseTGiniso-
caloric exchange for starch but not for su-
crose or mixed carbohydrate sources in
type 2 diabetes. These observations ﬁt
with proposed mechanisms. Fructose,
unlike glucose, bypasses the major rate-
limiting step of glycolysis (phophofruc-
tokinase), allowing fructose to serve as an
unregulated substrate for de novo lipo-
genesis (DNL). This model of metabolic
handling, however, is only supported by
hypercaloric fructose feeding (20% ex-
cess energy) trials (29,30). Other evi-
dence suggests a mechanism whereby
fructose decreases TG clearance by li-
poprotein lipase, due to decreased glu-
cose-stimulated insulin secretion and
increased chylomicron remnants (31).
On the other hand, the observed lack of
effect compared with sucrose and
mixed carbohydrates is probably ex-
plained by both sources necessarily
containing fructose as part of the su-
crose molecule. The implication is that
fructose may be no worse than other
fructose-containing nutritive sweeten-
ers in the diabetic diet.
Adosethresholdfortheeffectoffruc-
tose on TG was observed in type 2 diabe-
tes.Onlyatfructosedosesgreaterthanthe
CDA threshold of 60 g/day (12% en-
ergy for a 2,000-kcal diet) (5) was a TG-
raising effect observed in subgroup
analyses.Thisthresholdisconsistentwith
the 100 g/day identiﬁed across different
clinical states (7) and ﬁndings from hy-
percaloric feeding trials with fructose in-
takes at 25% excess energy in healthy
humans, the only trials in which a TG-
raising effect has been observed reliably
(29,30,32–35).Althoughourthresholdis
lower than these estimates, it is higher
than the estimated U.S. intake of total
fructose of 9.1% energy (45.5 g/day for a
2,000-kcal diet) (8). The inability of low
doses to stimulate a quantitatively mean-
ingful DNL response may explain this
threshold.WhereasDNLcontributes60–
70% TG in rodents (36), it only contrib-
utes 5% TG in humans, under longer
term, isocaloric, high-carbohydrate feed-
ing conditions (37). Alternatively, the
threshold may relate to the beneﬁt of cat-
alytic fructose doses (10 g/meal) in de-
creasing acute postprandial glycemic and
insulinemic responses in type 2 diabetes
(38), mediated by increased hepatic glu-
coseclearanceviaincreasedglycogensyn-
thase-ﬂux (39). The suggestion is that the
beneﬁt of fructose on carbohydrate me-
tabolismseenatlowerdosesmaymitigate
adverse lipid effects, which require high
doses to become manifest.
An effect of follow-up was also ob-
served in type 2 diabetes. Follow-up was
identiﬁed as the strongest independent
predictor of TG and total cholesterol, ex-
plaining 22–36% of the variation in these
outcomes. Only at follow-up 4 weeks
was a TG-raising effect seen. The lack of
Table 2—Primary pooled analyses of the effect of fructose exchange for carbohydrate on blood lipids
Outcome
No.
(studies)
No.
(subjects)
Effect estimate Heterogeneity
SMD (95% CI) P 
2 I
2 (%) P
TG
Any diabetes 16 236 0.01 (0.19–0.21) 0.9 36.75 59 0.001
Type 1 diabetes 4 54 0.03 (0.51–0.46) 0.91 10.96 73 0.01*
Type 2 diabetes 11 156 0.06 (0.17–0.30) 0.61 23.22 57 0.01†
Total cholesterol
Any diabetes 14 172 0.02 (0.18–0.14) 0.79 40.96 71 0.0001
Type 1 diabetes 2 14 0.17 (0.32–0.67) 0.49 5.45 82 0.02
Type 2 diabetes 11 132 0.08 (0.26–0.10) 0.37 32.29 72 0.0002
LDL cholesterol
Any diabetes 7 99 0.02 (0.07–0.11) 0.69 7.00 14 0.32
Type 1 diabetes 1 6 0.25 (0.03–0.53) 0.08 — — —
Type 2 diabetes 6 93 0.01 (0.10–0.09) 0.86 3.97 0 0.55
HDL cholesterol
Any diabetes 12 164 0.02 (0.05–0.10) 0.51 48.01 77 0.00001‡
Type 1 diabetes 1 6 0.01 (0.46–0.44) 0.96 — — —
Type 2 diabetes 10 132 0.02 (0.05–0.10) 0.53 47.95 81 0.00001‡
Analyses were performed by the generic inverse variance method using ﬁxed-effects or random-effects (if heterogeneity was signiﬁcant at P  0.10) models with
pairedanalysesappliedforcrossovertrials(12).—,noavailabledataforsubgroupanalysesor,iftherearenodataforheterogeneityinthepresenceofacorresponding
effectestimate,dataonlyavailablefromonestudy,precludingcalculationofI
2andthecorrespondingPvalue.*RemovalofOseietal.(20)duringsensitivityanalyses
explained heterogeneity (I
2  0%, P  0.59). †Removal of Osei and Bossetti (24) during sensitivity analyses explained heterogeneity (I
2  0%, P  0.88 for all
diabetes; I
2  0%, P  0.76 for type 2 diabetes).‡Removal of Pelkonen et al. (16) during sensitivity analyses explained heterogeneity (I
2  10%, P  0.33).
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ametabolicadaptationtoprolongedfruc-
tose feeding or decreased compliance due
to fructose malabsorption. In stark con-
trast to animal models fed fructose at
60% energy (40) to elicit metabolic de-
rangements without malabsorption, 80%
of humans fed 50 g/day (10% energy)
showevidenceofmalabsorption,whichis
mitigated by glucose (41). Alternatively,
trials that were 4 weeks may have had
protocols that better favored compliance.
In this regard, 8 of 11 trials that were 4
weeks were also metabolically controlled,
anindependentpredictorexplaining10%
of the variation in TG.
Otherfactorsaffectinglipidsintype2
diabetes include aspects of study quality,
design,andprotocol.Althoughnotsignif-
icant in univariate subgroup analyses,
crossover design was the strongest inde-
pendent predictor of TG. Fluid fructose
format was also positively associated with
TG. The main drivers of the total choles-
terol–lowering effect were crystalline
fructose, no metabolic control, dietary fat
intake 30% energy, no randomization,
and low study quality (MQS 8) in uni-
variate analyses and dose and follow-up,
as independent predictors in multivariate
analyses.
Interpretation of these pooled analy-
ses is complicated by several caveats.
First, only ﬁve trials lasted 12-weeks.
Whether the lack of effect on TG seen in
studiesof4weekspersistsoveralonger
term, therefore, is uncertain. Second, we
did not identify any eligible trials investi-
gating the effect of high-fructose corn
syrup, a main source of fructose as a
sweetener.Thisabsencewassurprisingas
high-fructose corn syrup has become one
of the dominant sweeteners in the U.S.,
owing to its increased functionality and
lowercost(42).Third,thesubgroupanal-
yses were underpowered to assess differ-
ences in one factor across the different
levels of the others. We did, however, at-
tempt to explore the relative contribution
of the subgroup factors with multiple re-
gressionmodels,althoughweareawareof
the limitation posed by performing these
analyses with so few studies. Finally, be-
cause only published studies were in-
cluded, publication bias remains a
possibility, although funnel plots showed
this to be improbable.
In summary, fructose used as a nutri-
tive sweetener in isocaloric exchange for
carbohydrateseemstohaveonlyamodest
TG-raising effect in type 2 diabetes at
doses 60 g/day with follow-up of 4
weeks or when the reference carbohy-
drate is starch. This effect is in addition to
amodesttotalcholesterol–loweringeffect
driven by markers of poor study quality,
Figure 2—Forest plots of signiﬁcant subgroup analyses of the effect of isocaloric exchange of fructose for carbohydrate on TGs (A–C) and total
cholesterol (TC) (D–G) in subjects with type 2 diabetes reported in 11 trials. Paired analyses were applied to all crossover trials, according to
Elbourne et al. (13). Data are SMDs with 95% CI, where an SMD is interpreted as follows: 0.4 represents a small effect size; 0.4–0.7 represents
a moderate effect size; and 0.7 represents a large effect size. P values are for generic inverse variance ﬁxed- and random-effects models. Interstudy
heterogeneity was tested by Cochrane’s Q (
2) at a signiﬁcance level of P  0.10 and quantiﬁed by I
2, where I
2  50% is considered to be evidence
ofsubstantialheterogeneityandI
275%isconsideredtobeconsiderableheterogeneity(11).StudyqualitywasassessedbytheHeylandMQS,where
MQS  8 is considered high quality (range 0–13) (14). Because the trials that were nonrandomized (NR) were identical to those that were scored
as low quality (MQS  8), the two subgroups were presented as a single forest plot. Fru, fructose; FU, follow-up; E, energy.
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30% energy. No other lipid effects were
detected. These data suggest that in the
context of low fructose intake as a nutri-
tive sweetener in exchange for other sug-
ars, concerns relating to adverse lipid
effects may not be justiﬁed. Nevertheless,
there is a clear imperative for well-
powered, long-term (6 months) ran-
domized controlled trials that investigate
fructose exchange for starch and sucrose
overawidedoserangeinindividualswith
type 2 diabetes to address the sources of
heterogeneity identiﬁed in the data. Fur-
ther meta-analyses of additional meta-
bolic parameters, including body weight,
glycemic control, and blood pressure, are
planned. Separate analyses of hyperca-
loric feeding trials are also warranted. In
the meantime, the heterogeneity in the
data should be considered in the formu-
lation of guidelines.
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